Literature DB >> 12134229

Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection.

R Renae Speck1, Xiao-Fang Yu, James Hildreth, Charles Flexner.   

Abstract

P-glycoprotein (P-gp) and multidrug-resistance protein-1 (MRP-1) are adenosine triphosphate-binding cassette proteins that may decrease intracellular concentrations of anti-human immunodeficiency virus (HIV) drugs. After HIV-1(IIIB) infection, HIV-1 protein and infectious virus production were decreased by at least 70-fold in CEM cells overexpressing P-gp but were increased by at least 50-fold in CEM cells overexpressing MRP-1, compared with control CEM cells. After transfection with the HIV-1(IIIB) genome, cells overexpressing P-gp and MRP-1 expressed similar amounts of HIV protein. Selective inhibitors of MRP-1 and P-gp partially reversed the effect of these transporters in a concentration-dependent manner. P-gp preferentially associated with glycolipid-enriched membrane (GEM) domains, which may be an important site for cellular binding and egress of HIV. In contrast, MRP-1 was not preferentially found in GEM domains. These results suggest that the inhibition of HIV productive infection by P-gp and augmentation by MRP-1 occur predominantly at a preintegration step but act through different mechanisms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12134229     DOI: 10.1086/341464

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

Review 1.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 2.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

3.  Antiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans.

Authors:  Erin Burgunder; John K Fallon; Nicole White; Amanda P Schauer; Craig Sykes; Leila Remling-Mulder; Martina Kovarova; Lourdes Adamson; Paul Luciw; J Victor Garcia; Ramesh Akkina; Philip C Smith; Angela D M Kashuba
Journal:  J Pharmacol Exp Ther       Date:  2019-06-24       Impact factor: 4.030

4.  Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis.

Authors:  Timothy J Spitzenberger; David Heilman; Casey Diekmann; Elena V Batrakova; Alexander V Kabanov; Howard E Gendelman; William F Elmquist; Yuri Persidsky
Journal:  J Cereb Blood Flow Metab       Date:  2006-10-25       Impact factor: 6.200

5.  The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages.

Authors:  Tzanko S Stantchev; Ingrid Markovic; William G Telford; Kathleen A Clouse; Christopher C Broder
Journal:  Virus Res       Date:  2006-10-09       Impact factor: 3.303

6.  Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors.

Authors:  Todd Hulgan; John P Donahue; Laura Smeaton; Minya Pu; Hongying Wang; Michael M Lederman; Kimberly Smith; Hernan Valdez; Christopher Pilcher; David W Haas
Journal:  Eur J Clin Pharmacol       Date:  2009-11       Impact factor: 2.953

7.  Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.

Authors:  Antonio Valentin; Matthew Morrow; Richard H Poirier; Karen Aleman; Richard Little; Robert Yarchoan; George N Pavlakis
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

8.  Differential expression levels of MRP1, MRP4, and MRP5 in response to human immunodeficiency virus infection in human macrophages.

Authors:  Sylvie Jorajuria; Nathalie Dereuddre-Bosquet; Karen Naissant-Storck; Dominique Dormont; Pascal Clayette
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment.

Authors:  Annemarie Shibata; Emily McMullen; Alex Pham; Michael Belshan; Bridget Sanford; You Zhou; Michael Goede; Abhijit A Date; Abjijit A Date; Christopher J Destache
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-01       Impact factor: 2.205

10.  Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4.

Authors:  Andrew Owen; Becky Chandler; Patrick G Bray; Stephen A Ward; C Anthony Hart; David J Back; Saye H Khoo
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.